Ab201 development as a potential treatment for covid-19 receives u.s. fda fast track designation

Westminster, colo., nov. 23, 2020 (globe newswire) -- arca biopharma, inc. (nasdaq: abio), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the u.s. food and drug administration (fda) has designated as a fast track development program the investigation of ab201 as a potential treatment for covid-19. the company intends to initiate a phase 2b clinical trial (aspen-covid-19) of ab201 in approximately 100 patients hospitalized with covid-19 in december 2020, with topline trial data anticipated in the second quarter of 2021.
ABIO Ratings Summary
ABIO Quant Ranking